2,3,5-三氯-6-甲氧基吡啶 | 31557-34-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,3,5-三氯-6-甲氧基吡啶
• 英文名称: 2,3,5-Trichloro-6-methoxypyridine
• CAS: 31557-34-3
• 化学式: C₆H₄Cl₃NO
• 分子量: 212.5
• InChiKey: RLIVUWLXZBDMBL-UHFFFAOYSA-N

物化性质

• 保留指数：
  1364.5

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  2,3,5-三氯-6-甲氧基吡啶 、 磺酰氯 以 四氯化碳 为溶剂， 反应 6.0h， 以to afford a pure fraction of 2-chloromethoxy-3,5,6-trichloropyridine, 52.5 g的产率得到2,3,5-Trichloro-6-chloromethoxy-pyridine
  参考文献：
  名称：

  Chloro-pyridinyloxymethyl esters of thiocyanic acid

  摘要：

  化学式为##STR1##的硫氰酸氯吡啶氧甲酯，其中N为1至4，M为1至3，X为H、F、CCl.sub.3或OCH.sub.2 Cl，取代基总数不超过5。这些化合物具有杀菌活性。这些化合物是通过将相应的氯吡啶与甲醇中的甲氧基钠混合形成相应的氯甲氧基吡啶，逐渐加入四氯化碳溶液中的亚磺酰氯形成相应的氯甲氧基氯吡啶，并加入硫氰酸钾形成产物硫氰酸氯吡啶氧甲酯制备的。

  公开号：

  US04062853A1
• 作为产物：
  描述：

  3,5,6-三氯吡啶-2-醇 、 碘甲烷 、 potassium carbonate 、 丙酮 生成 2,3,5-三氯-6-甲氧基吡啶
  参考文献：
  名称：

  NEELAKANTAN PARVATHI; RANI RENU; RAHMAN M. F.; BHALERAO U. T., INDIAN J. CHEM., 24,(1985) N 11, 1180-1181

  摘要：

  DOI：

文献信息

• NEELAKANTAN PARVATHI; RANI RENU; RAHMAN M. F.; BHALERAO U. T., INDIAN J. CHEM., 24,(1985) N 11, 1180-1181
  作者：NEELAKANTAN PARVATHI、 RANI RENU、 RAHMAN M. F.、 BHALERAO U. T.

  DOI：——

  日期：——
• PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS
  申请人：Seattle Children's Hospital (dba Seattle Children's Research Institute)

  公开号：US20200087399A1

  公开（公告）日：2020-03-19

  Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
• METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS
  申请人：Seattle Children's Hospital (dba Seattle Children's Research Institute)

  公开号：US20210317407A1

  公开（公告）日：2021-10-14

  Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
• AN INHIBITOR OF AN IRON-CONTAINING HYDROGENASE OF A METHANOGENIC ARCHAEON FOR USE IN THE TREATMENT OR PREVENTION OF A PARKINSONIAN CONDITION
  申请人：UNIVERSITE DU LUXEMBOURG

  公开号：US20220387368A1

  公开（公告）日：2022-12-08

  The present invention relates to an inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition, wherein said archaeon is in the gut of a subject and is characterized by the production of 2-hydroxypyridine. In addition, the present invention relates to a pharmaceutical composition comprising such an inhibitor and a kit comprising such an inhibitor. Further, the present invention relates to a method of screening for an inhibitor for use according to the present invention and a method for determining whether or not a subject is susceptible to a treatment with an inhibitor for use according to the present invention.
• METHOD FOR DETERMINING WHETHER OR NOT A SUBJECT HAS A PARKINSONIAN CONDITION
  申请人：UNIVERSITE DU LUXEMBOURG

  公开号：US20220404374A1

  公开（公告）日：2022-12-22

  The present invention relates to a method for determining whether or not a subject has a parkinsonian condition, comprising determining the concentration of 2-hydroxypyridine in a sample obtained from the subject, wherein the subject is determined to have, or to be at risk of having the parkinsonian condition, if the determined concentration of 2-hydroxypyridine is increased compared to a control. The present invention further also relates to a method for monitoring the progression of a parkinsonian condition in a subject diagnosed with the parkinsonian condition and a method for assessing the efficacy of treatment of a parkinsonian condition in a subject diagnosed with the parkinsonian condition as well as a kit-of-parts for determining whether or not a subject has a parkinsonian condition.